BioAge, a startup focused on developing therapies for obesity and metabolic diseases, announced its $170M Series D financing round. The funding round, led by Sofinnova and supported by top-tier healthcare investors including Lilly and Amgen, aims to advance BioAge's therapies, including a Phase 2-ready obesity drug and a combination therapy involving an experimental drug from BioAge and Zepbound. This development marks a significant step in BioAge's mission to decouple aging from disease and expedite the clinical development of their metabolic aging pipeline. In related news, Alys has launched with $100M in funding and a pipeline of skin disease drugs, showcasing the growing interest and investment in biotech innovations targeting unmet needs in dermatology and beyond.
Congrats to @bioagelabs on raising your Series D! We're so impressed by the impact and vision of the team. https://t.co/PSAecD03zJ
Congrats to @kpfortney & @bioagelabs on a $170M Series D round! This marks a major step in BioAge's mission to uncouple aging from disease with plans to expedite the clinical development of their metabolic aging pipeline. https://t.co/lR0Fd98Kqh
Startup BioAge raises $170 million Series D for Zepbound combination therapy https://t.co/260lIUo2oA via @ADeAngelis_bio for @statnews
BioAge raises $170M to back Phase 2-ready obesity drug https://t.co/G9BNuthDRk @ByJonGardner
Exciting day at BioAge! All made possible by our talented team, visionary investors, and focus on aging science. With our $170M Series D, we're advancing therapies that treat obesity and metabolic diseases to help build a healthier future. Excited for the journey ahead! https://t.co/uRzfWdmciY
The hope is that combining a BioAge experimental drug with Zepbound will lead to further weight loss with less muscle deterioration: Startup BioAge raises $170 million Series D for Zepbound combination therapy https://t.co/Rordx6CPIE via @statnews
BioAge is pleased to announce our $170M Series D financing to advance our therapies for obesity & metabolic diseases. The round was led by Sofinnova, with top-tier healthcare investors including key obesity strategics Lilly & Amgen. https://t.co/btG4yv7pRD (🧵 1/8)
Alys launches with $100M and a pipeline of skin disease drugs https://t.co/jZK9HSxwmd by @Lilah_Alvarado
Thanks @sciencescanner! Congrats to @fderubertis @HarrisVitiligo @Finlay_Jonny and the amazing team! I have no doubt that this will be the first #biotech company to transform how #dermatology #innovation is done across many unmet #diseases https://t.co/x80GRf4h9J